Supplementary Figures from miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma

Figure S1. Characterization of vemurafenib-resistant melanoma cells. Figure S2. Sensitivity of A375-VR cells to other inhibitors of the MAP kinase pathway. Figure S3. Characterization of invasive properties ofA375-VR cells and sensitivity to a Rac inhibitor. Figure S4. Characterization of miRNA expression in melanoma cells resistant to BRAF and MEK inhibitors, and in foreskin melanocytes. Figure S5. Overexpression or silencing of miRNAs in A375, SK-Mel 28 and A375-VR cells. Figure S6. Role of miR-204-5p, miR-211-5p and miR-140-3p in melanoma resistance to MAP kinase inhibitors and to AKT blockers. Figure S7. miRNA role in VMF resistance in BRAF wild type cells. Figure S8. Analyses of miRNA target expression in cells overexpressing miR-204-5p and miR-211-5p and in A375-VR cells.